AZ's Farxiga first in class to improve outcomes in heart fai...

AstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class to show efficacy in heart failure, in patients with or without type-2 diabe

Novo Nordisk faces $1.8 billion lawsuit over US insulin sale...

Novo Nordisk is facing a lawsuit from disgruntled investors seeking around $1.8 billion in compensation, saying the company failed to properly update the market about the situation regardin

NHS patients to receive digital diabetes prevention support

Thousands of patients at risk of type 2 diabetes are to receive digital support to help prevent them developing the condition as part of an expansion of these schemes on England’s NHS.

Novo extends R&D alliance with AI specialist e-Therapeutics

Sanofi ups revenues forecasts as eczema drug Dupixent surges

Sanofi has upped its revenue forecasts for the year on the back of strong second quarter results from its new eczema and asthma injection Dupixent and its rare diseases and vaccines busines

FDA clears Lilly’s rescue med for severe hypoglycaemia in di...